Angela A Wang, Felix Luessi, Tradite Neziraj, Elisabeth Pössnecker, Michelle Zuo, Sinah Engel, Nicholas Hanuscheck, Alexandra Florescu, Eryn Bugbee, Xianjie I Ma, Fatima Rana, Dennis Lee, Lesley A Ward, Jens Kuhle, Johannes Himbert, Muriel Schraad, Erwin van Puijenbroek, Christian Klein, Eduard Urich, Valeria Ramaglia, Anne-Katrin Pröbstel, Frauke Zipp, Jennifer L Gommerman
Anti-CD20 therapy to deplete B cells is highly efficacious in preventing new white matter lesions in patients with relapsing-remitting multiple sclerosis (RRMS), but its protective capacity against gray matter injury and axonal damage is unclear. In a passive experimental autoimmune encephalomyelitis (EAE) model whereby TH 17 cells promote brain leptomeningeal immune cell aggregates, we found that anti-CD20 treatment effectively spared myelin content and prevented myeloid cell activation, oxidative damage, and mitochondrial stress in the subpial gray matter...
March 6, 2024: Science Translational Medicine